Epidemiological and Clinical-pathological Factors of Philadelphia-negative Myeloproliferative Neoplasms in Ecuador

NCT05825326 | Completed

• 1 other identifier: CISOLGYE20230022
• Study Type: observational
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this observational study is to evaluate the epidemiological and clinical-pathological features of Philadelphia-negative myeloproliferative neoplasms through data from medical records

Conditions

Myeloproliferative Neoplasm; Myeloproliferative Syndrome; Myeloproliferative Neoplasm, Unclassifiable; Myeloproliferative Disorders; Myeloproliferative Disease, Not Classified

Keywords

Myeloproliferative Neoplasm

Outcome Measures

Primary Outcomes (1)

• Number of patients with Philadelphia-negative Myeloproliferative Neoplasms in Ecuador

  Participants were followed-up for 8 years. This is the number of participants who have had Philadelphia-negative Myeloproliferative Neoplasms in Ecuador during the time of observation.

  96 months

Secondary Outcomes (3)

• Prevalence of Philadelphia-negative myeloproliferative patients

  96 months

• Mortality risk as measured by the Dynamic International Prognostic Scoring System

  96 months

• Overall survival

  96 months

Study Arms (1)

Patients diagnosed with Philadelphia-negative Myeloproliferative Neoplasms

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients diagnosed with Philadelphia-negative Myeloproliferative Neoplasms according to the 2022 World Health Organization (WHO) classification

You may qualify if:

• years and older
• Patients with confirmed diagnosis of Philadelphia-negative Myeloproliferative Neoplasms

You may not qualify if:

• Patients with translocation t(9;22)(q34:q11.2) with subsequent formation of the BCR-ABL1 fusion gene determined by cytogenetics or fluorescence in situ hybridization (FISH)
• Absence of the histopathological report in the clinical history and the corresponding plaque, except in the case of Polycythemia Vera that does not require them for diagnosis, according to the 2022 WHO classification

Sponsors & Collaborators

• Sociedad de Lucha Contra el Cáncer del Ecuador: lead

Study Sites (1)

Sociedad de Lucha Contra el Cáncer

Guayaquil, Guayas, Ecuador

Location

Related Publications (6)

• Nangalia J, Green AR. Myeloproliferative neoplasms: from origins to outcomes. Blood. 2017 Dec 7;130(23):2475-2483. doi: 10.1182/blood-2017-06-782037.

  PMID: 29212804 BACKGROUND

• Heppner J, Nguyen LT, Guo M, Naugler C, Rashid-Kolvear F. Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada. BMC Res Notes. 2019 May 24;12(1):286. doi: 10.1186/s13104-019-4321-1.

  PMID: 31126326 BACKGROUND

• Hultcrantz M, Kristinsson SY, Andersson TM, Landgren O, Eloranta S, Derolf AR, Dickman PW, Bjorkholm M. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012 Aug 20;30(24):2995-3001. doi: 10.1200/JCO.2012.42.1925. Epub 2012 Jul 16.

  PMID: 22802311 BACKGROUND

• Roaldsnes C, Holst R, Frederiksen H, Ghanima W. Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway. Eur J Haematol. 2017 Jan;98(1):85-93. doi: 10.1111/ejh.12788. Epub 2016 Sep 4.

  PMID: 27500783 BACKGROUND

• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. Blood. 2016 Jul 21;128(3):462-463. doi: 10.1182/blood-2016-06-721662. No abstract available.

  PMID: 31659364 BACKGROUND

• Linardi Cda C, Pracchia LF, Buccheri V. Diagnosis and treatment of polycythemia vera: Brazilian experience from a single institution. Sao Paulo Med J. 2008 Jan 2;126(1):52-7. doi: 10.1590/s1516-31802008000100010.

  PMID: 18425288 BACKGROUND

MeSH Terms

Conditions

Myeloproliferative Disorders

Condition Hierarchy (Ancestors)

Bone Marrow Diseases; Hematologic Diseases; Hemic and Lymphatic Diseases

Study Officials

• Fuad Huamán Garaicoa, MD

  Sociedad de Lucha Contra el Cáncer del Ecuador

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 27, 2023
• First Posted: April 24, 2023
• Study Start: January 1, 2012
• Primary Completion: December 31, 2019
• Study Completion: December 31, 2019
• Last Updated: April 27, 2023

Record last verified: 2023-04

Locations

EC (1)